268.67 USD
-4.22
1.55%
At close Feb 14, 4:00 PM EST
After hours
268.67
+0.00
0.00%
1 day
-1.55%
5 days
3.21%
1 month
6.24%
3 months
15.06%
6 months
46.73%
Year to date
11.95%
1 year
0.13%
5 years
41.08%
10 years
550.53%
 

About: Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.

Employees: 4,200

0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 10 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 2 (+1) [Q3]

17% more call options, than puts

Call options by funds: $68.5M | Put options by funds: $58.6M

5% more capital invested

Capital invested by funds: $6.52B [Q2] → $6.87B (+$353M) [Q3]

9% less first-time investments, than exits

New positions opened: 51 | Existing positions closed: 56

2.47% less ownership

Funds ownership: 93.48% [Q2] → 91.0% (-2.47%) [Q3]

3% less funds holding

Funds holding: 339 [Q2] → 328 (-11) [Q3]

29% less repeat investments, than reductions

Existing positions increased: 98 | Existing positions reduced: 139

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$240
11%
downside
Avg. target
$277
3%
upside
High target
$323
20%
upside

10 analyst ratings

positive
80%
neutral
20%
negative
0%
Baird
David Rescott
81% 1-year accuracy
13 / 16 met price target
14%upside
$305
Outperform
Maintained
23 Jan 2025
UBS
Priya Sachdeva
0% 1-year accuracy
0 / 2 met price target
14%upside
$305
Buy
Initiated
21 Jan 2025
Truist Securities
Richard Newitter
74% 1-year accuracy
31 / 42 met price target
6%upside
$285
Buy
Maintained
18 Dec 2024
Oppenheimer
Steve Lichtman
100% 1-year accuracy
2 / 2 met price target
2%upside
$275
Outperform
Initiated
17 Dec 2024
Citigroup
Joanne Wuensch
66% 1-year accuracy
31 / 47 met price target
9%downside
$245
Neutral
Maintained
11 Dec 2024

Financial journalist opinion

Positive
Zacks Investment Research
4 days ago
Should You Add Penumbra Stock to Your Portfolio Right Now?
PEN continues to attract investor interest with its strong portfolio expansion and global expansion efforts.
Should You Add Penumbra Stock to Your Portfolio Right Now?
Neutral
PRNewsWire
3 weeks ago
Penumbra, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for February 18, 2025
ALAMEDA, Calif. , Jan. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2024 after market close on Tuesday, February 18, 2025 at 4:30 PM Eastern Time.
Penumbra, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for February 18, 2025
Positive
Zacks Investment Research
4 weeks ago
Buy 4 Low-Beta Stocks AVO, TXO, PEN & STRA to Beat Market Volatility
It is imperative to build a portfolio of low-beta stocks to navigate a volatile market. AVO, TXO, PEN & STRA are well-poised to gain.
Buy 4 Low-Beta Stocks AVO, TXO, PEN & STRA to Beat Market Volatility
Positive
Zacks Investment Research
1 month ago
3 Reasons Why Growth Investors Shouldn't Overlook Penumbra (PEN)
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
3 Reasons Why Growth Investors Shouldn't Overlook Penumbra (PEN)
Positive
Zacks Investment Research
1 month ago
5 Must-Buy Efficient Stocks to Increase Your Portfolio Returns
Invest in companies like YPF, TEF, PEN, DECK and ANF to make the most of higher efficiency levels.
5 Must-Buy Efficient Stocks to Increase Your Portfolio Returns
Positive
Zacks Investment Research
1 month ago
Penumbra (PEN) Surges 6.3%: Is This an Indication of Further Gains?
Penumbra (PEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Penumbra (PEN) Surges 6.3%: Is This an Indication of Further Gains?
Neutral
Zacks Investment Research
1 month ago
Reasons to Add Penumbra Stock to Your Portfolio Now
PEN stays on investors' radars due to its strong Thrombectomy business and international growth plans.
Reasons to Add Penumbra Stock to Your Portfolio Now
Neutral
Zacks Investment Research
1 month ago
IART or PEN: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Instruments sector might want to consider either Integra LifeSciences (IART) or Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?
IART or PEN: Which Is the Better Value Stock Right Now?
Neutral
PRNewsWire
1 month ago
Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ALAMEDA, Calif. , Dec. 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 43rd Annual J.P.
Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Positive
Zacks Investment Research
1 month ago
Is Penumbra (PEN) a Solid Growth Stock? 3 Reasons to Think "Yes"
Penumbra (PEN) could produce exceptional returns because of its solid growth attributes.
Is Penumbra (PEN) a Solid Growth Stock? 3 Reasons to Think "Yes"
Charts implemented using Lightweight Charts™